Obesity patients will have one more option to reduce their flab, FDA has approved a new prescription weight-loss pill Contrave. Contrave joins Qsymia (phentermine and topiramate) and Belviq (lorcaserin), which were approved in 2012. The mode of action is the same but the addition of Contrave adds one more drug in the doctor’s inventory for fighting obesity.
FDA was not satisfied with the information pertaining to the action of the drug on the heart. It therefore asked for fresh studies in 2011 to make sure that the drug did not have any adverse effects on the working of the heart. The approval has riders though; the manufacturers will have to do another study about the drug’s effects on the cardiovascular system.
John Foreyt, PhD, professor of medicine and director of the Behavioral Medicine Research Center at Baylor College of Medicine, Houston, explains how the drug acts by taking away hunger and cravings for food. The exact mode of action is still speculative and not fully understood by the scientists.
William Troy Donahoo, MD, an endocrinologist and weight loss specialist at Kaiser Permanente, Denver feels that bupropion helps lessen appetite and naltrexone works by blocking certain receptors in the brain and curbing cravings.
The drug has an OD dosage and is recommended for adults with a BMI of 30 categorized as obese or BMI value of 27 which is categorized as overweight. Persons with BMI between 30 and 27 face elevated risks of heart and stroke as well as high blood pressure, cholesterol, or type II diabetes.
The drug is contraindicated in persons suffering from a seizure disorder, pregnant women or those trying to get pregnant, or anyone with an eating disorder, among others, according to the FDA.